Welcome to our dedicated page for Nordson SEC filings (Ticker: NDSN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nordson’s precision dispensing empire spans packaging lines, medical catheters, and smartphone solder paste—yet its SEC reports bury the details in technical language and segment footnotes. If you have ever wondered “Nordson SEC filings explained simply” or hunted for adhesive systems revenue inside a 300-page annual report, you know the challenge.
Stock Titan solves that puzzle. Our AI reads every Nordson annual report 10-K simplified, breaks down segment backlog movements, and flags supply-chain risk shifts. Real-time alerts surface Nordson Form 4 insider transactions the moment they post, so you can track Nordson executive stock transactions Form 4 without refreshing EDGAR. Want the latest numbers? The platform delivers a concise wrap-up of each Nordson quarterly earnings report 10-Q filing alongside charts, ratios, and peer comparisons—ideal for quick “Nordson earnings report filing analysis.”
All core documents are one click away: 8-Ks for acquisition news (Nordson 8-K material events explained), DEF 14A for Nordson proxy statement executive compensation, and every Nordson insider trading Form 4 transactions notice, streamed Nordson Form 4 insider transactions real-time. Our AI-powered summaries, expert commentary, and historical archive let professionals monitor R&D spend, compare quarter-over-quarter margins, and understand compliance changes—no spreadsheet wrangling required. Stop scrolling through dense PDFs and start understanding Nordson SEC documents with AI.
Form 4 filing for Antero Midstream Corp. (AM) discloses that director Brooks J. Klimley acquired 2,042 shares of AM common stock on 07 July 2025. The shares were received at a stated price of $0.00, implying a grant rather than an open-market purchase. Following the transaction, Klimley’s direct beneficial ownership increased to 75,687 shares. No derivative securities were reported.
The filing is routine in nature, reflecting a modest change in insider ownership and does not provide additional financial or strategic information about Antero Midstream.
Salarius Pharmaceuticals, Inc. ("SLRX") filed an 8-K to report that on 10 July 2025 it received a decision from the Nasdaq Hearings Panel granting additional time to regain listing compliance.
- Equity Standard – Rule 5550(b)(1): deadline extended from early-July to late-July 2025.
- Minimum Bid Price – Rule 5550(a)(2): deadline remains early-August 2025.
Background events include a March 26 2025 notice that stockholders’ equity fell below the required threshold and an April 23 2025 delisting notice for trading below the $1.00 bid-price minimum for 30 consecutive business days. Because Salarius completed a reverse stock split within the prior year, it was ineligible for the usual 180-day cure period.
The company appealed, automatically staying delisting. A prior extension was granted on 11 June 2025; the latest ruling lengthens only the equity-compliance deadline and is contingent on milestone reporting. Failure to meet either requirement by the new dates is expected to lead to suspension and delisting from The Nasdaq Capital Market.
No operating results, financing transactions, or strategic updates were provided; the filing focuses solely on Nasdaq listing status.
FAQ
What is the current stock price of Nordson (NDSN)?
What is the market cap of Nordson (NDSN)?
What is the primary focus of Nordson Corporation?
How does Nordson generate revenue?
Which industries benefit from Nordson's products?
How is the company structured?
What differentiates Nordson from its competitors?
Where is Nordson Corporation headquartered?
How does Nordson approach innovation in its products?
What role does customer support play in Nordson's business model?
